Travel grant 2024 Switzerland, Swiss Nordic Bio 2024 on March 7
| Reference number | |
| Coordinator | PILA PHARMA AB |
| Funding from Vinnova | SEK 15 000 |
| Project duration | March 2024 - March 2024 |
| Status | Completed |
| Venture | Global cooperation 2024 |
Important results from the project
The objective for the conference was to meet and engage with potential Swiss investors and pharma companies that we had not yet had any dialogue with. We had a range of productive first-hand meetings and we consider it a success that we got in touch with a segment of investors we normally don´t have access to or meet. Thus the goals prior to the conference have been met.
Expected long term effects
A range of productive first-hand meetings with potential prospective investors we had not previously met. No pharma companies of interest were participating on the day.
Approach and implementation
We had a 10 minute presentation followed by lunch mingle and 1-to-1 meetings with prospective investors. The meetings were all productive and have opened new dialogues for the company.